IndiumV1, Main, Exploration, bibRecord, 000208

Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas

Identifieur interne : 000208 ( Main/Exploration ); précédent : 000207; suivant : 000209

Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas

Auteurs : RBID : ISTEX:12013_1994_Article_BF02789242.pdf

English descriptors

KwdEn :
- Chromogranin A, Human antiavidin response, Human antimouse antibody, Immunoscintigraphy.

Abstract

For various pituitary adenomas, it has been demonstrated that somatostatin receptor can be present. Pilot studies have shown that radio-indium labeled pentetreotide allows very good scintigraphic localization of somatostatin receptor-bearing cell masses. Recently, the presence of CgA in pituitary adenomas has also been demonstrated. MAb A11, raised against CgA, has been successfully used with a three-step ISG for the diagnosis of neuroendocrine tumors. Therefore the combined use of three-step ISG with MAb A11 and radiolabeled somatostatin can be useful in the diagnosis of pituitary adenomas. Twelve patients, 5 secreting (group A) and 7 nonsecreting (group B) pituitary adenomas, were enrolled in the study. All patients underwent three-step ISG, and, 2 wk later, scintigraphy with111In-labeled pentetreotide (Octreoscan). Three-step ISG consisted of iv injection of 1 mg of biotinylated MAb A11 (first step), followed by 10 mg of avidin (second step) and [99mTc]PnAO-biotin (third step). Tomographic imaging were acquired for three-step ISG and Octreoscan at 2 and 4 h after radiotracer injection, respectively. The results are the following: 2 patients of group A (secreting tumors) had a positive three-step ISG, whereas all the patients but one of the same group had a positive pentetreotide study; all the patients of group B (nonsecreting tumors) had a positive three-step ISG and 4 had a positive pentetreotide scintigraphy. These data suggest the utility of the combined use of these techniques for a better diagnosis of pituitary adenomas.

DOI: 10.1007/BF02789242

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000333
to stream Main, to step Curation: 000333

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title>Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas</title>
<author><name>P. Magnani</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
<author><name>G. Paganelli</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
<author><name>A. G. Siccardi</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
<author><name>C. Songini</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
<author><name>P. Colombo</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
<author><name>G. Faglia</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
<author><name>F. Fazio</name>
<affiliation wicri:level="1"><mods:affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS Ospedale Maggiore, University of Milan, Milan</wicri:regionArea>
<wicri:noRegion>Milan</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="RBID">ISTEX:12013_1994_Article_BF02789242.pdf</idno>
<date when="1994">1994</date>
<idno type="doi">10.1007/BF02789242</idno>
<idno type="wicri:Area/Main/Corpus">000333</idno>
<idno type="wicri:Area/Main/Curation">000333</idno>
<idno type="wicri:Area/Main/Exploration">000208</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chromogranin A</term>
<term>Human antiavidin response</term>
<term>Human antimouse antibody</term>
<term>Immunoscintigraphy</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">For various pituitary adenomas, it has been demonstrated that somatostatin receptor can be present. Pilot studies have shown that radio-indium labeled pentetreotide allows very good scintigraphic localization of somatostatin receptor-bearing cell masses. Recently, the presence of CgA in pituitary adenomas has also been demonstrated. MAb A11, raised against CgA, has been successfully used with a three-step ISG for the diagnosis of neuroendocrine tumors. Therefore the combined use of three-step ISG with MAb A11 and radiolabeled somatostatin can be useful in the diagnosis of pituitary adenomas. Twelve patients, 5 secreting (group A) and 7 nonsecreting (group B) pituitary adenomas, were enrolled in the study. All patients underwent three-step ISG, and, 2 wk later, scintigraphy with111In-labeled pentetreotide (Octreoscan). Three-step ISG consisted of iv injection of 1 mg of biotinylated MAb A11 (first step), followed by 10 mg of avidin (second step) and [99mTc]PnAO-biotin (third step). Tomographic imaging were acquired for three-step ISG and Octreoscan at 2 and 4 h after radiotracer injection, respectively. The results are the following: 2 patients of group A (secreting tumors) had a positive three-step ISG, whereas all the patients but one of the same group had a positive pentetreotide study; all the patients of group B (nonsecreting tumors) had a positive three-step ISG and 4 had a positive pentetreotide scintigraphy. These data suggest the utility of the combined use of these techniques for a better diagnosis of pituitary adenomas.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="3863cfbbf5ed488d5caa2f9feee2ecb86fbd8600"><titleInfo lang="eng"><title>Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas</title>
</titleInfo>
<name type="personal"><namePart type="given">P.</namePart>
<namePart type="family">Magnani</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<name type="personal"><namePart type="given">G.</namePart>
<namePart type="family">Paganelli</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<name type="personal"><namePart type="given">A. G.</namePart>
<namePart type="family">Siccardi</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">Songini</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<name type="personal"><namePart type="given">P.</namePart>
<namePart type="family">Colombo</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<name type="personal"><namePart type="given">G.</namePart>
<namePart type="family">Faglia</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<name type="personal"><namePart type="given">F.</namePart>
<namePart type="family">Fazio</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>INB-CNR, DIBIT, IRCCS H S. Raffaele, Via Olgettina 60, I-20132, Milan, Italy</affiliation>
<affiliation>IRCCS Ospedale Maggiore, University of Milan, Milan, Italy</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Paper</genre>
<originInfo><publisher>Humana Press, Totowa</publisher>
<dateValid encoding="w3cdtf">2007-12-17</dateValid>
<copyrightDate encoding="w3cdtf">1994</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">For various pituitary adenomas, it has been demonstrated that somatostatin receptor can be present. Pilot studies have shown that radio-indium labeled pentetreotide allows very good scintigraphic localization of somatostatin receptor-bearing cell masses. Recently, the presence of CgA in pituitary adenomas has also been demonstrated. MAb A11, raised against CgA, has been successfully used with a three-step ISG for the diagnosis of neuroendocrine tumors. Therefore the combined use of three-step ISG with MAb A11 and radiolabeled somatostatin can be useful in the diagnosis of pituitary adenomas. Twelve patients, 5 secreting (group A) and 7 nonsecreting (group B) pituitary adenomas, were enrolled in the study. All patients underwent three-step ISG, and, 2 wk later, scintigraphy with111In-labeled pentetreotide (Octreoscan). Three-step ISG consisted of iv injection of 1 mg of biotinylated MAb A11 (first step), followed by 10 mg of avidin (second step) and [99mTc]PnAO-biotin (third step). Tomographic imaging were acquired for three-step ISG and Octreoscan at 2 and 4 h after radiotracer injection, respectively. The results are the following: 2 patients of group A (secreting tumors) had a positive three-step ISG, whereas all the patients but one of the same group had a positive pentetreotide study; all the patients of group B (nonsecreting tumors) had a positive three-step ISG and 4 had a positive pentetreotide scintigraphy. These data suggest the utility of the combined use of these techniques for a better diagnosis of pituitary adenomas.</abstract>
<subject lang="eng"><genre>Index Entries</genre>
<topic>Immunoscintigraphy</topic>
<topic>chromogranin A</topic>
<topic>human antiavidin response</topic>
<topic>human antimouse antibody</topic>
</subject>
<relatedItem type="series"><titleInfo type="abbreviated"><title>Cell Biophysics</title>
</titleInfo>
<titleInfo><title>Cell Biophysics</title>
<partNumber>Year: 1994</partNumber>
<partNumber>Volume: 24-25</partNumber>
<partNumber>Number: 1-3</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo><dateIssued encoding="w3cdtf">1994-01-01</dateIssued>
<copyrightDate encoding="w3cdtf">1994</copyrightDate>
</originInfo>
<subject usage="primary"><topic>Life Sciences</topic>
<topic>Biochemistry, general</topic>
<topic>Pharmacology/Toxicology</topic>
<topic>Biotechnology</topic>
<topic>Cell Biology</topic>
</subject>
<identifier type="issn">0163-4992</identifier>
<identifier type="issn">Electronic: 1559-0283</identifier>
<identifier type="matrixNumber">12013</identifier>
<identifier type="local">IssueArticleCount: 37</identifier>
<recordInfo><recordOrigin>Humana Press Inc., 1994</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF02789242</identifier>
<identifier type="matrixNumber">Art35</identifier>
<identifier type="local">BF02789242</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part><extent unit="pages"><start>307</start>
<end>313</end>
</extent>
</part>
<recordInfo><recordOrigin>Humana Press Inc., 1994</recordOrigin>
<recordIdentifier>12013_1994_Article_BF02789242.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000208 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000208 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:12013_1994_Article_BF02789242.pdf
   |texte=   Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas
}}

This area was generated with Dilib version V0.5.81.
Data generation: Mon Aug 25 10:35:12 2014. Site generation: Thu Mar 7 10:08:40 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas

Combined use of111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin a monoclonal antibody in the diagnosis of pituitary adenomas

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri